Skip to Content

Eli Lilly and Co LLY Stock Quote

| Rating as of

Morningstar‘s Stock Analysis LLY

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Despite Weak Quarter, Lilly Is Well Positioned for Long Term, but Stock Is Priced for Perfection

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Eli Lilly reported weak second-quarter results slightly below our projections, but we do not expect any major changes to our fair value estimate based on the minor shortfall. Importantly, older drugs drove most of the weakness, while most of the key recently launched drugs continue to post steady gains. These next-generation drugs are the most important factor supporting Lilly’s wide moat. While these newer drugs are posting strong gains, we continue to view the stock as moderately overvalued, with the market expecting near-perfect launches and excellent late-stage development (especially from phase 3 Alzheimer’s drug donanemab).

Unlock Our Full Analysis With Morningstar Investor

Key Statistics LLY

Company Profile LLY

Business Description

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Contact
Lilly Corporate Center
Indianapolis, IN, 46285
T +1 317 276-2000
Industry Drug Manufacturers - General
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Classic Growth
Employees 35,000

Related News LLY